Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. reports developments in mRNA medicines, including commercial vaccines, investigational respiratory vaccines, oncology programs and rare-disease candidates. News commonly covers regulatory authorizations and agency interactions for products such as Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX, as well as clinical data for seasonal influenza, pandemic influenza and cancer immunotherapy programs including intismeran autogene and mRNA-4359.
Company updates also include quarterly financial results, revenue mix, expense actions, strategic partnerships, scientific meeting presentations and intellectual-property matters tied to Moderna's infectious disease portfolio and broader mRNA technology platform.
Moderna (NASDAQ:MRNA) will report fourth quarter 2025 financial results on Friday, February 13, 2026 with a live conference call and webcast at 8:00 a.m. ET. The company will also provide a corporate update during the call.
A live webcast will be available under Events and Presentations in the Investors section of Moderna's website. The archived webcast will be posted about two hours after the call and will remain available for one year.
Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) reported median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study showing that intismeran autogene plus KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; 95% CI 0.294-0.887; one-sided nominal p=0.0075) versus KEYTRUDA alone in patients with resected high-risk stage III/IV melanoma.
The safety profile remained consistent with prior reports. Moderna and Merck plan further follow-up presentations and continue enrollment across eight Phase 2/3 studies, with the Phase 3 adjuvant melanoma trial fully enrolled.
Moderna (NASDAQ:MRNA) provided business and pipeline updates at the 44th J.P. Morgan Healthcare Conference on January 12, 2026. The company expects 2025 revenue ≈ $1.9B (unaudited), improved GAAP operating expense outlook to $5.0–$5.2B, and year-end cash ≈ $8.1B. Moderna reiterated a target of up to 10% revenue growth in 2026, expects GAAP operating expenses of ~$4.9B in 2026, and aims for cash breakeven by 2028. Key 2026 catalysts include potential approvals for seasonal flu and flu/COVID vaccines and multiple pivotal data readouts across oncology, rare disease, and infectious disease.
Moderna (NASDAQ:MRNA) filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 with the FDA, EMA, Health Canada and the TGA in Australia for adults aged 50 and older on January 5, 2026.
Regulatory applications rely on positive Phase 3 data: in study P304 mRNA-1010 met a prespecified superiority criterion with a relative vaccine efficacy (rVE) of 26.6% (95% CI 16.7%–35.4%) across adults ≥50 and an rVE of 27.4% in participants ≥65. Prior study P303 showed superior seroconversion rates and GMRs versus high-dose and standard-dose licensed vaccines. Safety was described as favorable, with most solicited adverse reactions reported as mild.
Moderna (NASDAQ:MRNA) and CEPI announced up to $54.3 million in funding to support a pivotal Phase 3 trial of Moderna's investigational mRNA H5 pandemic influenza vaccine candidate, mRNA-1018. The Phase 3 study is planned to begin early 2026 in the UK and U.S. and follows positive Phase 1/2 immune-response data.
If licensed, Moderna will allocate 20% of H5 manufacturing capacity for timely supply to low- and middle-income countries at affordable pricing.
Moderna (Nasdaq: MRNA) will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12 at 7:30 p.m. ET / 4:30 p.m. PT. A live webcast will be available under "Events and Presentations" in the Investors section at investors.modernatx.com. A replay will be archived on Moderna's website for at least 30 days following the presentation.
Moderna (NASDAQ:MRNA) said the EMA's CHMP adopted a positive opinion recommending marketing authorization of mNEXSPIKE (mRNA-1283) for prevention of COVID-19 in individuals aged 12 years and older. The recommendation follows a Phase 3 trial of ~11,400 participants that reported a 9.3% higher relative vaccine efficacy versus mRNA-1273 and a 13.5% higher rVE in adults aged 65+. Safety was similar to mRNA-1273 with fewer local reactions. The European Commission will decide on authorization; if approved, Moderna expects to make mNEXSPIKE available in EU markets pending regulatory timelines and local access pathways. Moderna noted prior approvals from the U.S. FDA and Health Canada.
Moderna (NASDAQ:MRNA) outlined a three-year strategy on November 20, 2025, targeting up to 10% revenue growth in 2026 and a path to cash breakeven in 2028. The company plans to expand its seasonal vaccine franchise from three to as many as six approved products by 2028 and expects readouts from nine ongoing Phase 2 and Phase 3 oncology studies, including three Phase 3 programs for intismeran.
Moderna lowered expected cash costs to about $4.2B in 2026 and $3.5–$3.9B in 2027, projects a >10 percentage-point gross margin improvement over three years, and closed a $1.5B five-year term loan, updating year-end cash to $7.1–$7.6B.
Moderna (NASDAQ:MRNA) closed a five-year non-dilutive term loan facility for up to $1.5 billion with Ares Management Credit Funds on November 20, 2025.
The facility includes a $600 million initial term loan funded at closing, a $400 million delayed-draw term loan available through November 2027, and an additional $500 million delayed-draw tranche available through November 2028 that is contingent on achievement of key regulatory milestones aligned with Moderna's late-stage clinical pipeline.
Moderna reiterated its 2025 financial guidance and reaffirmed a target to reach cash breakeven by 2028. The company also scheduled an Analyst Day webcast for November 20, 2025 at 9:00 a.m. ET.
Moderna (NASDAQ:MRNA) is expanding U.S. manufacturing by onshoring Drug Product capabilities to its Moderna Technology Center in Norwood, Massachusetts. The project includes a >$140 million investment and is expected to create hundreds of biomanufacturing jobs, enabling full end-to-end mRNA manufacturing in the U.S. for commercial and clinical supply. Construction has started and Moderna is targeting completion by the first half of 2027. The move reinforces Moderna's domestic manufacturing footprint and supports its pipeline of mRNA vaccines and therapeutics across infectious diseases, cancer, rare diseases, and autoimmune disorders.